Greenwich, CT, December 13, 2021 Silver Point Finance, a subsidiary of Silver Point Capital, L.P., served as syndication agent and lead lender in the financing of a $375 million Senior Secured Term Loan to Pacira BioSciences, Inc. (“Pacira”). Proceeds will be used for general corporate purposes, including supporting Pacira’s acquisition of Flexion Therapeutics. JPMorgan Chase Bank, N.A. acted as bookrunner and lead arranger.
About Pacira
Pacira BioSciences, Inc. (Nasdaq: PCRX) is committed to providing a non-opioid option to as many patients as possible to redefine the role of opioids as rescue therapy only. Pacira is also developing innovative interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain, and spasticity. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting, local analgesia currently approved for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular, injection indicated for the management of osteoarthritis knee pain, and ioveraº, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit
www.pacira.com.